Original news and analysis on international IP policy
A 12-year-old World Health Organization programme for prequalifying medical products has helped international organisations and others to safely purchase billions of US dollars' worth of quality medicines per year, but now is at risk due to funding shortages, a new study released today found.
World Health Organization member governments have been working for several years to agree on ways to prevent the spread of dangerous and misleading substandard and fake medical products. Now, they seem to be moving in the direction of concrete action.
The United Nations Office on Drugs and Crime (UNODC) today launched a major awareness-raising campaign against trafficking in counterfeit goods, which it said is a major revenue source for organised crime worldwide: $250 billion per year.
Just weeks before being abruptly arrested and strip-searched in New York, a now-departed Indian diplomat took on the powerful US business lobby over India’s controversial approach to intellectual property.
Looking back on 2013, the list of the most-viewed stories on the Intellectual Property Watch website shows that reporting on activities in India, especially related to patents and public health, continued to draw the most attention. Other top stories were the Marrakesh Treaty on copyright exceptions for blind readers, legal cases involving patents on seeds and on plant and human genes, the election for World Intellectual Property Organization director general, free-trade agreements (including the Wikileaks leak of the IP chapter of the Trans-Atlantic Partnership agreement), Russian copyrights, and 3D printing.
An upcoming conference in Mumbai, India will look at patent laws related to the pharmaceutical and biopharma industries regionally and internationally.
CPhI's 3rd Annual Pharma IPR 2014, taking place from 26-28 February, is a targeted conference focusing on patent related matters for pharma and biopharma industry across the globe. It is intended to provide an ideal learning and networking platform where techno-legal experts from patent law firms across the globe share an update on patent regimes, changes in patent laws, and enforceability of patent laws in different regions with the pharma and biopharma companies.
The conference agenda will cover most debated subjects like: inter-partes review; one year after the implementation of the America Invents Act; reverse payments settlements cases; current implementation of the Unitary Patent System in the EU; and formulating strategies to introduce generic products in international markets.
The programme will cover patent laws of over 13 regions including the US, EU, Japan, Mexico, Canada, India, South East Asia, and Gulf Corporation Council (GCC) countries.
Click here to view the region-wise agenda.
Free download for IP-Watch Readers! Click here to view presentations from 2013!
A new private-sector report shows that after a downturn, patents on a range of technologies for water are back on the rise as companies are busy innovating around a basic human need and resource.
The Berne Declaration, a Swiss non-profit, has released results of investigations that found industry-sponsored offshore clinical drug trials in developing countries involve "multiple ethical violations," a problem increased by the patent-based industry business model.
Following the public outcry over the EU’s demands for stringent intellectual property rules that would dramatically raise medicines prices in India, you would expect the EU to think twice about making similar demands in future trade agreements, particularly with low- and middle-income countries. Yet, this is precisely what is going on now in the negotiations for a free trade agreement between the EU and Thailand, writes Tessel Mellema.
The Medicines Patent Pool today announced a new agreement with biopharmaceutical company Bristol-Myers Squibb for an HIV medicine, which is expected to increase access in 110 developing countries.
CAPE TOWN, SOUTH AFRICA - Public groups this week urged Mark Dybul, head of the Geneva-based Global Fund for HIV, Tuberculosis and Malaria, to reconsider the establishment of a panel to look at tiered pricing for middle income countries, potentially allowing companies to charge them higher prices. And separately, activists reported on progress in South Africa's HIV strategy.
CAPE TOWN, SOUTH AFRICA - Intellectual property rights represent a hurdle to lower-priced, high quality tests of HIV treatment monitoring in developing countries, public health group Médecins Sans Frontières (MSF, Doctors without Borders) said today.